Vimian Group AB Logo

Vimian Group AB

Global animal health company in pharma, medtech, diagnostics, and vet services.

VIMIAN | ST

Overview

Corporate Details

ISIN(s):
SE0015961982 (+2 more)
LEI:
549300OQ8R5TCAP0BS18
Country:
Sweden
Address:
Riddargatan 19, 114 57 Stockholm

Description

Vimian Group is a global animal health company that applies science and technology to improve animal well-being. The company operates across four main segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. Through its portfolio of businesses, Vimian develops, manufactures, and distributes a wide range of products and services, including pharmaceuticals, medical devices, diagnostic tools, and specialized veterinary care. Its growth strategy combines in-house research and development with the acquisition of innovative companies to expand its offerings for veterinary professionals, clinics, and laboratories.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-30 17:30
Förändring av antalet aktier och röster i Vimian
Swedish 104.4 KB
2025-12-30 17:30
Change in the number of shares and votes in Vimian
English 104.1 KB
2025-12-22 21:30
Vimian har beslutat om nyemission och återköp av ytterligare D-aktier, E1 2025-…
Swedish 110.0 KB
2025-12-22 21:30
Vimian has resolved to issue and repurchase additional class D shares, class E1…
English 109.8 KB
2025-11-28 17:30
Change in the number of shares and votes in Vimian
English 106.5 KB
2025-11-28 17:30
Förändring av antalet aktier och röster i Vimian
Swedish 106.7 KB
2025-11-24 07:15
Vimian Group AB (publ) appoints Alireza Tajbakhsh as CEO
English 111.4 KB
2025-11-24 07:15
Vimian Group AB (publ) utser Alireza Tajbakhsh till vd och koncernchef
Swedish 111.3 KB
2025-10-27 07:00
Vimian has resolved to issue and repurchase class D shares, class E1 2025 share…
English 101.0 KB
2025-10-27 07:00
Vimian har beslutat om nyemission och återköp av D-aktier, E1 2025-aktier, E2 2…
Swedish 101.1 KB
2025-10-22 07:45 Swedish 2.0 MB
2025-10-22 07:45 English 1.9 MB
2025-09-23 10:00
Nomination Committee for Vimian’s 2026 Annual General Meeting
English 97.6 KB
2025-09-23 10:00
Valberedning inför Vimians årsstämma 2026
Swedish 97.6 KB
2025-08-30 01:03
Superior Court of Delaware awards Vimian USD 40.2 million in indemnification di…
English 108.1 KB

Automate Your Workflow. Get a real-time feed of all Vimian Group AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vimian Group AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vimian Group AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-14 Sven Johan Magnus Göte Kjellberg Other Sell 425,000 19,167,500.00 SEK
2024-12-23 Sven Johan Magnus Göte Kjellberg Other Sell 25,000 1,026,000.00 SEK

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.